共 95 条
[1]
Stupp R(2005)Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma N Engl J Med 352 987-996
[2]
Mason WP(2020)Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 Randomized Clinical Trial JAMA Oncol 6 1003-1010
[3]
van den Bent MJ(2017)Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma J Neurooncol 136 115-125
[4]
Reardon DA(2012)Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma Neuro Oncol 14 808-816
[5]
Brandes AA(2020)Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study Support Care Cancer 28 3267-3278
[6]
Omuro A(2014)The association between cognitive functioning and health-related quality of life in low-grade glioma patients Neurooncol Pract 1 40-46
[7]
Duerinck J(2019)The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials Eur J Cancer 116 190-198
[8]
Four SD(2007)The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC brain Tumour and Radiation Oncology groups, and NCIC Clinical Trials Group study Br J Cancer 97 302-307
[9]
Bouttens F(2000)Cognitive function as a predictor of survival in patients with recurrent malignant glioma J Clin Oncol 18 646-650
[10]
Johnson DR(2003)The prognostic value of cognitive functioning in the survival of patients with high-grade glioma Neurology 61 1796-1798